Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...

G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness ...

The MarketWatch News Department was not involved in the creation of this content. Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- ...

A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common gut bacteria can metabolize certain oral medications that target cellular ...

A couple of analysts initiated coverage on Septerna, Inc. (NASDAQ:SEPN), which debuted on NASDAQ last month. Cantor analyst Josh Schimmer initiated coverage at an Overweight rating with a price target ...

Collaboration Combines Best-in-Class Biology with Agile AI and Chemistry Automation for Rapid Discovery of Better Molecules for Highly Valuable G Protein-Coupled Receptor (GPCR) Targets MENLO PARK, ...